Search

Author/Creator Cakana, Andrew

1. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Issue 13 (18th May 2016)

Authors:
Orlowski, Robert Z.; Nagler, Arnon; Sonneveld, Pieter; Bladé, Joan; Hajek, Roman; Spencer, Andrew; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J.; Suvorov, Alexander N.; Xiu, Liang; Cakana, Andrew; Parekh, Trilok; San‐Miguel, Jesús F.
Journal:
Cancer
Issue:
Volume 122:Issue 13(2016)
Page Start:
2050
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The Cost‐Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment. (8th January 2013)

Authors:
Garrison, Louis P.; Wang, Si‐Tien; Huang, Hui; Ba‐Mancini, Abbie; Shi, Hongliang; Chen, Kristina; Korves, Caroline; Dhawan, Ravinder; Cakana, Andrew; van de Velde, Helgi; Corzo, Deyanira; Duh, Mei Sheng
Journal:
Oncologist
Issue:
Volume 18:Number 1(2013)
Page Start:
27
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search